Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results.
Lōkahi Therapeutics, a GlucoTrack unit, introduced Qare, a real-time comparative health platform focused on GLP-1 medications. Public availability is scheduled to begin on Oct. 14, 2026, following an initial introduction timed to National GLP-1 Day. Platform targets cohort-based comparisons of patient-reported treatmen
Glucotrack announced Qare, a real-time comparative health platform for GLP-1 medications, with public availability expected Oct. 14, 2026. The platform targets patient-reported treatment comparisons across GLP-1 products.
Lōkahi Therapeutics, a subsidiary of Glucotrack, Inc., has launched Qare™, a new comparative health platform designed to evaluate treatment outcomes by comparing patient experiences across different medications within the same therapeutic class, specifically for GLP-1 medications. The platform becomes publicly availabl
Lōkahi Therapeutics, a subsidiary of Glucotrack Inc. (NASDAQ: GCTK), announced Qare™, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. The platform is expected to become publicly available on Oct